Company / Revenue per Share
Gain Therapeutics, Inc. Revenue per Share History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue per Share
$0.00
FY2024
5-year range
$0.00 / $0.01
FY2021-FY2024
Trend
-71.1%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $0.01 to $0.00 over the past 2 years.
Based on SEC 10-K filings.
0.00 in FY2024 with a 3-year CAGR of -25.2%.
Declined from $0.01 to $0.00 over the past 2 years.
Revenue per Share over time
Growth rates
- 3-Year CAGR
- -25.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, revenue per share decreased 71.1% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Revenue per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $0.00 | -71.1% |
| FY2023 | $0.01 | -15.1% |
| FY2022 | $0.01 | +70.3% |
| FY2021 | $0.01 | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026